IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (Nasdaq: TKAI). Investors who purchased or otherwise acquired shares between June 24, 2015 and July 25, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the September 30, 2016 lead plaintiff motion deadline.
If you purchased shares of Tokai during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the complaint, Tokai made false and misleading statements and/or failed to disclose that: there were significant structural problems with the trial design for its Phase 3 galeterone study, ARMOR3-SV; that ARMOR3-SV was unlikely to succeed in meeting its primary endpoint; the commercialization of galeterone was less likely than investors were led to believe; and as a result of the above, Tokai’s statements about its business, operations, and prospects were false and misleading at all relevant times.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.